ATE389019T1 - Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen - Google Patents

Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen

Info

Publication number
ATE389019T1
ATE389019T1 AT00961688T AT00961688T ATE389019T1 AT E389019 T1 ATE389019 T1 AT E389019T1 AT 00961688 T AT00961688 T AT 00961688T AT 00961688 T AT00961688 T AT 00961688T AT E389019 T1 ATE389019 T1 AT E389019T1
Authority
AT
Austria
Prior art keywords
interleukin
antibody
combinations
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
AT00961688T
Other languages
English (en)
Inventor
Birgit Oppmann
Waal Malefyt Rene De
Donna Rennick
Robert Kastelein
Maria Wiekowski
Sergio Lira
Satwant Narula
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26860707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE389019(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE389019T1 publication Critical patent/ATE389019T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
AT00961688T 1999-09-09 2000-09-08 Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen ATE389019T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39309099A 1999-09-09 1999-09-09
US16461699P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
ATE389019T1 true ATE389019T1 (de) 2008-03-15

Family

ID=26860707

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961688T ATE389019T1 (de) 1999-09-09 2000-09-08 Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen

Country Status (15)

Country Link
EP (1) EP1210434B2 (de)
JP (6) JP4505166B2 (de)
KR (1) KR100894359B1 (de)
CN (1) CN100529076C (de)
AR (1) AR035560A1 (de)
AT (1) ATE389019T1 (de)
AU (2) AU780163B2 (de)
CA (1) CA2388562C (de)
DE (1) DE60038304T3 (de)
ES (1) ES2300276T5 (de)
HK (1) HK1044170B (de)
HU (1) HU230679B1 (de)
IL (1) IL148300A0 (de)
MX (1) MXPA02002684A (de)
WO (1) WO2001018051A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202362B2 (en) * 1999-09-03 2011-06-23 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
MXPA02011081A (es) 2000-05-10 2003-03-10 Schering Corp Proteinas de subunidad de receptor de citocina de mamifero, reactivos y metodos relacionados.
DE60328823D1 (de) 2002-10-30 2009-09-24 Genentech Inc Hemmung von il-17 produktion
ATE515514T1 (de) 2002-12-23 2011-07-15 Schering Corp Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
ES2330220T3 (es) * 2003-03-10 2009-12-07 Schering Corporation Usos de antagonistas de il-23; reactivos relacionados.
JP2007515939A (ja) 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
EP1522858A1 (de) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methoden für Selektion von Verbindungen unter Verwendung von Antikörpern mit Aktivität als Agonist, Antagonist oder allosterischen Modulatoren
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006068987A2 (en) * 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
US7872102B2 (en) * 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
SG165322A1 (en) 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
PL1971366T3 (pl) 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
DK1966238T3 (da) 2005-12-30 2012-07-16 Merck Patent Gmbh INTERLEUKIN-12P40-varianter med forbedret stabilitet
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
JP5337055B2 (ja) 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
US8119133B2 (en) 2007-02-28 2012-02-21 Schering Corporation Engineered anti-IL-23R antibodies
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
JPWO2009133863A1 (ja) * 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2850093B1 (de) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutische il-13-polypeptide
EP4039275A1 (de) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19-antikörper
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014171721A1 (ko) * 2013-04-16 2014-10-23 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
KR101625112B1 (ko) 2013-04-16 2016-05-27 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
CN113563478A (zh) 2013-09-24 2021-10-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
EP3172339A1 (de) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarker zur verwendung bei der behandlung von erkrankungen im zusammenhang mit il-23a
BR112017004169A2 (pt) 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
JP6219875B2 (ja) * 2015-04-10 2017-10-25 株式会社スクウェア・エニックス ネットワークゲームシステム、ゲーム装置及びプログラム
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN114317430A (zh) * 2021-12-28 2022-04-12 河北银丰鼎诚生物技术有限公司 一种适用于脐血来源免疫细胞扩增的培养液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368112T1 (de) * 1989-12-22 2007-08-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 40kd untereinheit und monoklonale antikörper spezifisch dafür
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
JP2001503257A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド Ｉｌ―１２遺伝子発現および送達系および使用
PE20000183A1 (es) * 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
WO1999040195A1 (en) * 1998-02-06 1999-08-12 Schering Corporation Mammalian receptor proteins; related reagents and methods

Also Published As

Publication number Publication date
JP2009268467A (ja) 2009-11-19
AU2008240348A1 (en) 2008-11-27
CA2388562C (en) 2014-07-22
DE60038304D1 (de) 2008-04-24
JP2010233571A (ja) 2010-10-21
HUP0301102A3 (en) 2005-11-28
WO2001018051A3 (en) 2001-09-20
EP1210434B1 (de) 2008-03-12
HU230679B1 (en) 2017-08-28
AU7360800A (en) 2001-04-10
CN100529076C (zh) 2009-08-19
JP2003510038A (ja) 2003-03-18
EP1210434B2 (de) 2016-12-14
DE60038304T3 (de) 2017-04-06
EP1210434A2 (de) 2002-06-05
IL148300A0 (en) 2002-09-12
JP2007045830A (ja) 2007-02-22
KR20020034185A (ko) 2002-05-08
CA2388562A1 (en) 2001-03-15
CN1387571A (zh) 2002-12-25
JP6140122B2 (ja) 2017-05-31
ES2300276T5 (es) 2017-06-02
KR100894359B1 (ko) 2009-04-22
AR035560A1 (es) 2004-06-16
JP4969610B2 (ja) 2012-07-04
AU780163B2 (en) 2005-03-03
JP2015051005A (ja) 2015-03-19
DE60038304T2 (de) 2009-03-19
JP4505166B2 (ja) 2010-07-21
HK1044170A1 (en) 2002-10-11
ES2300276T3 (es) 2008-06-16
HUP0301102A2 (hu) 2003-07-28
WO2001018051A2 (en) 2001-03-15
JP2013128489A (ja) 2013-07-04
AU2008240348B2 (en) 2012-07-12
HK1044170B (zh) 2008-08-01
MXPA02002684A (es) 2002-07-30

Similar Documents

Publication Publication Date Title
ATE389019T1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
DE60029115D1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE69840552D1 (de) Verbindungen und Pharmazeutische Zusammensetzungen mit appetitunterdrückender Aktivität
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
ATE280583T1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
DE69816471D1 (de) Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE69300913T2 (de) Polymorph Terazosin und pharmazeutische Zusammenstellung.
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE69524592D1 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
ATE252096T1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
DE69809928D1 (de) Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen
DE60109279D1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
EE04316B1 (et) Asolotriasiinid ja -pürimidiinid, neid sisaldavadfarmatseutilised kompositsioonid ning nende kasutamine ravimite valmistamiseks
ATE332140T1 (de) Pharmazeutische zusammensetzungen, welche steroidische strukturen enthalten, und deren verwendungen
IT1291823B1 (it) Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
DE60126046D1 (de) Bizyklische Amino-Pyrazon Derivate, deren Herstellung und pharmazeutische Zusammensetzungen
DE69813624D1 (de) Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
DE60137952D1 (de) Pharmazeutische zusammensetzungen mit epinastin und pseudoephedrin
DE60214533D1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
ATE279927T1 (de) Pharmazeutische zusammensetzungen enthaltend tobramycin und xanthangummi
DE69900336T2 (de) Pentoxifyllin und antizytokin enthaltende pharmazeutische zusammensetzungen
SE9904414D0 (sv) Pharmaceutical composition and use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties